We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer

This study has been terminated.
(slow accrual)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00531687
First Posted: September 19, 2007
Last Update Posted: October 3, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Gedske Daugaard, Rigshospitalet, Denmark
  Purpose

Study Objectives:

Primary objective

  • The primary objective of this study is to investigate the combination of cisplatin/gemcitabine/paclitaxel, with respect to complete remission in patients with germ cell tumours previously treated with BEP.

Secondary Objectives

  • Overall survival
  • Progression free survival
  • Response rates (RECIST)
  • Duration of response
  • To investigate the safety of paclitaxel, gemcitabine and cisplatin in patients previously treated with BEP

Condition Intervention Phase
Testicular Cancer Drug: Paclitaxel Drug: Cisplatin Drug: Gemcitabine Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer

Resource links provided by NLM:


Further study details as provided by Gedske Daugaard, Rigshospitalet, Denmark:

Primary Outcome Measures:
  • Primary objective · The primary objective of this study is to investigate the combination of cisplatin/gemcitabine/paclitaxel, with respect to complete remission in patients with germ cell tumours previously treated with BEP. · · [ Time Frame: December 2010 ]

Secondary Outcome Measures:
  • Secondary Objectives · Overall survival [ Time Frame: 5 years ]
  • Secondary Objectives · Progression free survival [ Time Frame: 5 years ]
  • Secondary Objectives · Response rates (RECIST) [ Time Frame: 5 years ]
  • Secondary Objectives · Duration of response [ Time Frame: 5 years ]
  • Secondary Objectives · To investigate the safety of paclitaxel, gemcitabine and cisplatin in patients previously treated with BEP [ Time Frame: 5 years ]

Enrollment: 8
Study Start Date: September 2007
Study Completion Date: October 2016
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
GCT
cisplatin Paclitaxel gemcitabine
Drug: Paclitaxel

Paclitaxel 175 mg/m2 day 1 (3 hour infusion)

Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered.

Other Name: taxol
Drug: Cisplatin

cisplatin 50 mg/m2 day 1 and 2

Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered.

Drug: Gemcitabine

gemcitabine 1000mg/m2 days 1 and 8 (in a 30 minute infusion)

Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered

Other Name: Gemzar

Detailed Description:
not relevant
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed germ cell tumor (seminoma or non-seminoma) with measurable metastatic disease either by radiography (at a site which has previously not been irradiated) or elevation of alpha fetoprotein (AFP) and/or elevation of beta-human chorionic gonadotropin (beta-HCG);
  • Patient previously treated with standard BEP (3 or 4 cycles) with relapse 1 months or more after favorable response on previous chemotherapy (CR or PR)
  • Male
  • Age greater than or equal to 18 years;
  • Performance status 0,1,2 or 3
  • WBC > 3000 mill/l, ANC > 1500 mill/l, platelet count > 100.000 mill/l; serum bilirubin < 1.5 x the upper limit of normal;
  • Adequate renal function (Glomerular Filtration Rate (GFR) >60 ml/min). GFR will be assessed by direct measurement (EDTA clearance or creatinine clearance)
  • signed informed consent;

Exclusion Criteria:

  • Uncontrolled active severe clinical infection (CTC grade 3 or 4).
  • Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator), including expected difficulty of follow-up related to mental disorders.
  • Grade 2 or greater peripheral neuropathy according to the CTC, version 3.0.
  • Second malignancy other than basal or squamous cell skin cancer.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00531687


Locations
Denmark
Department of Oncology 5073, Rigshospitalet
Copenhagen, Denmark, 2100
Sponsors and Collaborators
Rigshospitalet, Denmark
Investigators
Principal Investigator: Gedske Daugaard, MD, DMSc Rigshospitalet, Denmark
  More Information

Responsible Party: Gedske Daugaard, Associate professor, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier: NCT00531687     History of Changes
Other Study ID Numbers: Relapse testis cancer 2007
First Submitted: September 18, 2007
First Posted: September 19, 2007
Last Update Posted: October 3, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Gedske Daugaard, Rigshospitalet, Denmark:
relapse

Additional relevant MeSH terms:
Testicular Neoplasms
Neoplasms, Germ Cell and Embryonal
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Genital Diseases, Male
Endocrine System Diseases
Testicular Diseases
Gonadal Disorders
Neoplasms by Histologic Type
Paclitaxel
Gemcitabine
Albumin-Bound Paclitaxel
Cisplatin
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antimetabolites
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs